Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Richey, Stephen L
RAMP 203, NCT05074810: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients	Recruiting	1/2	153	Europe, US	avutometinib and sotorasib, AMG 510, LUMAKRAS™, VS-6766, avutometinib and sotorasib and defactinib, VS-6063	Verastem, Inc., Amgen	Non Small Cell Lung Cancer, KRAS Activating Mutation	09/25	04/27
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors Oct 2019 - Mar 2020 : From AMBER trial From AMBER trial at SITC 2018 [screenshot] Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot] From AMBER trial in combination with TSR-022 at SITC 2018 Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018	Recruiting	1	447	Europe, US, RoW	TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin	Tesaro, Inc.	Neoplasms	04/25	04/27